Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Newer IMiDs

  • Chapter
  • First Online:
Advances in Biology and Therapy of Multiple Myeloma

  • 567 Accesses

Abstract

With the advent of thalidomide, the treatment of multiple myeloma was revolutionized. The drug showed excellent response rates in both previously untreated and relapsed/refractory patients. However, treatment-related toxicities such as somnolence, constipation, and neuropathy were a major limitation to its use. Lenalidomide, a thalidomide analogue, was developed with the hope of improving both the efficacy and toxicity profile of thalidomide and has subsequently shown significant clinical activity in patients with multiple myeloma. Though approved only for relapsed/refractory patients till date, clinical trials using lenalidomide with or without combinations have shown great efficacy in newly diagnosed, as a maintenance therapy and even asymptomatic myeloma. The recent introduction of another thalidomide analogue-pomalidomide has shown significant activity and a great potential for use in relapsed/refractory myeloma including those refractory to lenalidomide and bortezomib.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Muller GW, Chen R, Huang SY et al (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625–1630

    Article  PubMed  CAS  Google Scholar 

  2. Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520

    Article  PubMed  CAS  Google Scholar 

  3. Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386

    PubMed  CAS  Google Scholar 

  4. Lichtenstein A, Tu Y, Fady C et al (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162(2):248–255

    Article  PubMed  CAS  Google Scholar 

  5. Breitkreutz I, Raab MS, Vallet S et al (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10):1925–1932

    Article  PubMed  CAS  Google Scholar 

  6. Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31(2–3):213–221

    Article  PubMed  CAS  Google Scholar 

  7. Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063–3067

    Article  PubMed  CAS  Google Scholar 

  8. Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39(7–8):1489–1499

    Article  PubMed  CAS  Google Scholar 

  9. Sharpe AH, Abbas AK (2006) T-cell costimulation–biology, therapeutic potential, and challenges. N Engl J Med 355(10):973–975

    Article  PubMed  CAS  Google Scholar 

  10. Dredge K, Marriott JB, Todryk SM et al (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168(10):4914–4919

    PubMed  CAS  Google Scholar 

  11. Stirling D (2001) Thalidomide: a novel template for anticancer drugs. Semin Oncol 28(6):602–606

    Article  PubMed  CAS  Google Scholar 

  12. Hayashi T, Hideshima T, Akiyama M et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128(2):192–203

    Article  PubMed  CAS  Google Scholar 

  13. D’Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9):4082–4085

    Article  PubMed  Google Scholar 

  14. Dredge K, Marriott JB, Macdonald CD et al (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87(10):1166–1172

    Article  PubMed  CAS  Google Scholar 

  15. Shadduck RK, Latsko JM, Rossetti JM et al (2007) Recent advances in myelodysplastic syndromes. Exp Hematol 35(4 Suppl 1):137–143

    Article  PubMed  CAS  Google Scholar 

  16. Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961

    Article  PubMed  CAS  Google Scholar 

  17. Teo SK (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7(1):E14–E19

    Article  PubMed  CAS  Google Scholar 

  18. Dredge K, Horsfall R, Robinson SP et al (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1–2):56–63

    Article  PubMed  CAS  Google Scholar 

  19. Gandhi AK, Kang J, Naziruddin S et al (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849–858

    Article  PubMed  CAS  Google Scholar 

  20. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4(4):314–322

    Article  PubMed  CAS  Google Scholar 

  21. Verhelle D, Corral LG, Wong K et al (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67(2):746–755

    Article  PubMed  CAS  Google Scholar 

  22. Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96(9):2943–2950

    PubMed  CAS  Google Scholar 

  23. Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12):4525–4530

    Article  PubMed  CAS  Google Scholar 

  24. Mitsiades CS, Mitsiades NS, Richardson PG et al (2007) Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 101(4):950–968

    Article  PubMed  CAS  Google Scholar 

  25. RevAssist® for Prescribers. http://www.revlimid.com. Accessed april 2010 (2010)

  26. Dimopoulos MA, Chen C, Spencer A et al (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11):2147–2152

    Article  PubMed  CAS  Google Scholar 

  27. Chen C, Reece DE, Siegel D et al (2009) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 146(2):164–170

    Article  PubMed  CAS  Google Scholar 

  28. Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10):3458–3464

    Article  PubMed  CAS  Google Scholar 

  29. Richardson P, Jagannath S, Hussein M et al (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114(4):772–778

    Article  PubMed  CAS  Google Scholar 

  30. Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133–2142

    Article  PubMed  CAS  Google Scholar 

  31. Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123–2132

    Article  PubMed  CAS  Google Scholar 

  32. Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679–686

    Article  PubMed  CAS  Google Scholar 

  33. Richardson PG, Siegel D, Baz R et al (2010a) A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH Annual Meeting Abstracts 116(21):864

    Google Scholar 

  34. Dimopoulos MA, Kastritis E, Christoulas D et al (2010) Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24(10):1769–1778

    Article  PubMed  CAS  Google Scholar 

  35. Zonder JA, Crowley J, Hussein MA et al (2010) Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116(26):5838–5841

    Article  PubMed  CAS  Google Scholar 

  36. Rajkumar SV, Jacobus S, Callander NS et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29–37

    Article  PubMed  CAS  Google Scholar 

  37. Gay F, Hayman SR, Lacy MQ et al (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115(7):1343–1350

    Article  PubMed  CAS  Google Scholar 

  38. Palumbo A, Falco P, Corradini P et al (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian multiple myeloma network. J Clin Oncol 25(28):4459–4465

    Article  PubMed  CAS  Google Scholar 

  39. Lonial S, Baz R, Swern AS et al (2009) Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. ASH Annual Meeting Abstracts 114(22):2879-

    Google Scholar 

  40. Ishak J, Dimopoulos MA, Weber D et al (2008) Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. ASH Annual Meeting Abstracts 112(11):3708-

    Google Scholar 

  41. Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079–2080

    Article  PubMed  Google Scholar 

  42. Zonder JA (2006) Thrombotic complications of myeloma therapy. Hematology 2006(1):348–355

    Article  Google Scholar 

  43. Cavallo F, Raimondo FD, Harda I et al (2010) A phase III study of enoxaparin vs aspirin as thromboprophylaxis for newly diagnosed myeloma patients treated with lenalidomide-based regimen. ASH Annual Meeting Abstracts 116(21):1092-

    Google Scholar 

  44. Klein U, Kosely F, Hillengass J et al (2009) Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 88(1):67–71

    Article  PubMed  CAS  Google Scholar 

  45. Kneppers E, Lokhorst HM, Eeltink CM et al (2010) Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 10(2):138–143

    Article  PubMed  CAS  Google Scholar 

  46. Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423

    Article  PubMed  CAS  Google Scholar 

  47. Menon SP, Rajkumar SV, Lacy M et al (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112(7):1522–1528

    Article  PubMed  CAS  Google Scholar 

  48. Minnema MC, Breitkreutz I, Auwerda JJ et al (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18(12):2044–2046

    Article  PubMed  CAS  Google Scholar 

  49. Dimopoulos MA, Palumbo A, Attal M et al (2011) Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 25(5):749–760

    Article  PubMed  CAS  Google Scholar 

  50. Delforge M, Facon T, Bravo M-L et al (2009) Lenalidomide plus dexamethasone has similar tolerability and efficacy in treatment of relapsed/refractory multiple myeloma patients with or without history of neuropathy. ASH Annual Meeting Abstracts 114(22):3873-

    Google Scholar 

  51. Sviggum HP, Davis MD, Rajkumar SV et al (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142(10):1298–1302

    Article  PubMed  CAS  Google Scholar 

  52. Darabi K, Kantamnei S, Wiernik PH (2006) Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 24(35):e59

    Article  PubMed  Google Scholar 

  53. Harousseau JL, Dimopoulos MA, Wang M et al (2010) Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10):1738–1744

    Article  PubMed  CAS  Google Scholar 

  54. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al (2011) Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 11(1):38–43

    Google Scholar 

  55. Reece D, Song KW, Fu T et al (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114(3):522–525

    Article  PubMed  CAS  Google Scholar 

  56. Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25):3892–3901

    Article  PubMed  CAS  Google Scholar 

  57. Anderson KC, Jagannath S, Jakubowiak A et al (2009) Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. ASCO Meeting Abstracts 27(15S):8536

    Google Scholar 

  58. Richardson P, Jagannath S, Jakubowiak A et al (2008) Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. ASH Annual Meeting Abstracts 112(11):1742.

    Google Scholar 

  59. Zonder JA, Barlogie B, Durie BGM et al (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108(1):403–404

    Article  PubMed  CAS  Google Scholar 

  60. Baz R, Patel M, Finley-Oliver E et al (2010) Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 51(6):1015–1019

    Article  PubMed  CAS  Google Scholar 

  61. Palumbo A, Falco P, Benevolo G et al (2010) A multicenter, open label study of oral lenalidomide and prednisone (RP) followed by oral lenalidomide melphalan and prednisone (MPR) and oral lenalidomide maintenance in newly diagnosed elderly multiple myeloma patients. ASH Annual Meeting Abstracts 116(21):1940

    Google Scholar 

  62. Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294

    Article  PubMed  CAS  Google Scholar 

  63. Barlogie B, Pineda-Roman M, van Rhee F et al (2008) Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112(8):3115–3121

    Article  PubMed  CAS  Google Scholar 

  64. Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030

    Article  PubMed  CAS  Google Scholar 

  65. Spencer A, Prince HM, Roberts AW et al (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27(11):1788–1793

    Article  PubMed  CAS  Google Scholar 

  66. McCarthy PL, Owzar K, Anderson KC et al (2010) Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts 28 (15_suppl):8017

    Google Scholar 

  67. Attal M, Cristini C, Marit G et al (2010) Lenalidomide maintenance after transplantation for myeloma. ASCO Meeting Abstracts 28(15_suppl):8018

    Google Scholar 

  68. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749–757

    Article  Google Scholar 

  69. Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582–2590

    Article  PubMed  CAS  Google Scholar 

  70. Barlogie B, van Rhee F, Shaughnessy JD Jr et al (2008) Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112(8):3122–3125

    Article  PubMed  CAS  Google Scholar 

  71. Rajkumar SV, Gertz MA, Lacy MQ et al (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17(4):775–779

    Article  PubMed  CAS  Google Scholar 

  72. Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16–19

    Article  PubMed  CAS  Google Scholar 

  73. Mateos M-V, Lopez-Corral L, Hernandez MT et al. (2009) Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic mm: results of the first interim analysis. ASH Annual Meeting Abstracts 114(22):614

    Google Scholar 

  74. Galustian C, Meyer B, Labarthe MC et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58(7):1033–1045

    Article  PubMed  CAS  Google Scholar 

  75. Schey SA, Fields P, Bartlett JB et al (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22(16):3269–3276

    Article  PubMed  CAS  Google Scholar 

  76. Anderson G, Gries M, Kurihara N et al (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107(8):3098–3105

    Article  PubMed  CAS  Google Scholar 

  77. Ferguson GD, Jensen-Pergakes K, Wilkey C et al (2007) Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 27(2):210–220

    Article  PubMed  CAS  Google Scholar 

  78. Streetly MJ, Gyertson K, Daniel Y et al (2008) Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141(1):41–51

    Article  PubMed  CAS  Google Scholar 

  79. Lacy MQ, Hayman SR, Gertz MA et al (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27(30):5008–5014

    Article  PubMed  CAS  Google Scholar 

  80. Lacy MQ, Hayman SR, Gertz MA et al (2010) Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24(11):1934–1939

    Article  PubMed  CAS  Google Scholar 

  81. Lacy M, Mandrekar S, Gertz MAA et al (2010a) Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. ASH Annual Meeting Abstracts 116(21):863-

    Google Scholar 

  82. Leleu X, Attal M, Moreau P et al (2010) Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009–02. ASH Annual Meeting Abstracts 116(21):859-

    Google Scholar 

  83. Begna KH, Mesa RA, Pardanani A et al (2011) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25(2):301–304

    Article  PubMed  CAS  Google Scholar 

  84. Streetly M, Stewart O, Gyertson K et al (2009) Pomalidomide monotherapy for relapsed myeloma is associated with excellent responses and prolonged progression free and overall survival. ASH Annual Meeting Abstracts 114(22):3878

    Google Scholar 

  85. Short KD, Rajkumar SV, Larson D et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25(6):906–908

    Article  PubMed  CAS  Google Scholar 

  86. Baz R, Walker E, Karam MA, et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 17(12):1766–1771

    Article  PubMed  CAS  Google Scholar 

  87. Knop S, Gerecke C, Liebisch P, et al (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113(18):4137–4143

    Article  PubMed  CAS  Google Scholar 

  88. Morgan GJ, Schey SA, Wu P, et al (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137(13):268–269

    Article  PubMed  CAS  Google Scholar 

  89. Schey SA, Morgan GJ, Ramasamy K, et al (2010) The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology 150(3):326–333

    Article  PubMed  CAS  Google Scholar 

  90. Reece DE, Masih-Khan E, Khan A, et al (2010) Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid(R)) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 116:3055

    Article  PubMed  CAS  Google Scholar 

  91. Lacy MQ, Gertz MA, Dispenzieri A, et al (2007) Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings 82(10):1179–1184

    Article  PubMed  CAS  Google Scholar 

  92. Niesvizky R, Jayabalan DS, Christos PJ, et al (2008) BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111(3):1101–1109

    Article  PubMed  CAS  Google Scholar 

  93. Kumar SK, Flinn I, Noga SJ, et al (2010) Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 24(7):1350–1356

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    Abhishek Singla M.D. & Shaji Kumar M.D.

Authors
  1. Abhishek Singla M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaji Kumar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaji Kumar M.D. .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44 44, Boston, 02115, Massachusetts, USA

    Nikhil C. Munshi

  2. Dana-Farber Cancer Institute, Dept. Medical Oncology, Harvard Medical School, Binney St. 44, Boston, 02115, Massachusetts, USA

    Kenneth C. Anderson

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Singla, A., Kumar, S. (2013). Newer IMiDs. In: Munshi, N., Anderson, K. (eds) Advances in Biology and Therapy of Multiple Myeloma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5260-7_8

Download citation

Publish with us

Policies and ethics

Search

Navigation